NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) — Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from the CEOs of: Nova Mentis Life Sciences (NMLSF) ( CSE: NOVA), Novavax ( NVAX), Stealth BioTherapeutics ( MITO) and PharmaDrug ( LMLLF) (CSE: PHRX). As the global pharmaceutical market surpasses $1.3 trillion (Statista), emerging technologies and healthcare research innovations are unlocking new opportunities for exponential growth. As the biotech sector rebounds from cyclical lows, institutional investors are increasingly eyeing early-stage biotech stocks for alpha-generating upside potential. The Wall Street Reporter highlights the latest comments from industry thought leaders who are shaping our world today and in the decades to come:
Stanley C. Erck, CEO of Novavax (NVAX): “Innovative Approach to Traditional Vaccine Technology”
Novavax (NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, reports that the U.S. Food and Drug Administration’s Vaccines and Related Biologicals Advisory Committee voted 21 to 0, with one abstention, to recommend that the FDA grant emergency use authorization for the Novavax COVID-19 vaccine (NVX-CoV2373) for persons 18 years of age and older. NVAX CEO Stanley C. Erck commented, “The positive recommendation from the advisory board recognizes the strength of our data and the importance of a protein-based COVID-19 vaccine developed using an approach innovation in traditional vaccine technology. In line with submissions to regulatory authorities worldwide, we have already submitted an amendment with updated EUA manufacturing information to the FDA for review. We look forward to working with the FDA as they make their final decision.
News from Novavax (NVAX): https://www.wallstreetreporter.com/2022/06/08/fda-advisory-committee-recommends-emergency-use-authorization-of-novavax/
Nova Mentis Life Sciences (NMLSF) (CST: NOVA) CMO Marvin Hausman, MD: “Nova Psilocybin-based therapeutic showing great promise for autism and Othe Neuro-inflammatory disorders »
Nova Mentis Life Sciences (NMLSF) (CSE:NOVA), a guest presenter at Wall Street Reporter’s NEXT SUPER STOCK investor conference, is advancing new psilocybin therapies, targeting autism spectrum disorders, a medical need not satisfied with a multi-billion dollar market potential. NMLSF’s Chief Medical Officer, Dr. Marvin Hausman, MD, has decades of success promoting new drugs through FDA regulatory pathways, through to commercialization, generating billions of dollars in revenue. Dr. Hausman is now bringing the “same playbook” to NMLSF for his psilocybin therapies targeting Fragile X, and then potential expansion to treat other neuroinflammatory disorders, including Alzheimer’s and Parkinson’s. The NMLSF plans to submit a clinical trial application to Health Canada for a Phase 2A study evaluating its psilocybin microdose therapy for fragile X syndrome in the coming weeks.
NMLSF is a world leader in first-class psilocybin therapies and complementary diagnostics for neuroinflammatory disorders. NMLSF is the first biotechnology company to obtain “Orphan Drug Designation” from the FDA in the United States and European Union for the use of psilocybin in the treatment of FXS. In his interview with The Wall Street Reporter, Dr. Hausman explains his strategy for advancing NMLSF’s drug pipeline through commercialization, as he has successfully done with other new drugs over his decades-long career. .
Watch the NEXT SUPER STOCK Nova Mentis (NMLSF) (CSE:NOVA) video: https://www.wallstreetreporter.com/2022/03/25/next-super-stock-nova-mentis-life-sciences-otc-nmlsf-billions-opportunity-w-autism-psilocybin/
“The recently completed preclinical study of repeating low doses of our psilocybin drug – every other day for 2 weeks, showed clinical responses that far exceeded our expectations. We significantly modulated behavioral and cognitive defects , such as recognition memory, in the FXS.” The NMLSF plans to submit a clinical trial application to Health Canada in the coming weeks for a Phase 2A study evaluating psilocybin microdose therapy for FXS. “Autism Spectrum Disorders (“ASD”) and in particular FXS, the largest genetic cause of ASD, continue to have unmet medical needs. NOVA scientists over the past two years have cast the groundwork for the development of a potential new psilocybin-based microdose treatment for ASD,” said NMLSF Chief Medical Officer Dr. Marvin S. Hausman, MD.
Watch the NEXT SUPER STOCK Nova Mentis (NMLSF) (CSE:NOVA) video: https://www.wallstreetreporter.com/2022/03/25/next-super-stock-nova-mentis-life-sciences-otc-nmlsf-billions-opportunity-w-autism-psilocybin/
PharmaDrug (LMMLF) (CSE: PHRX) CEO Dan Cohen: “Advancing the drug pipeline by addressing billion-dollar markets”
PharmaDrug (LMMLLF) (CSE: PHRX) CEO Dan Cohen, guest presenter at Wall Street Reporter’s NEXT SUPER STOCK investor conference, advances a pipeline of naturally-based drugs, addressing multi-billion dollar market opportunities dollars in cancer, antiviral and glaucoma indications. The LMLLF now has four drug candidates progressing to clinical trials, with key milestones in the coming weeks.
Watch the NEXT SUPER STOCK PharmaDrug ( LMLLF) (CSE: PHRX) video: https://www.wallstreetreporter.com/2022/03/31/next-super-stock-pharmadrug-otc-lmllf-cse-phrx-advancing-biopharm-assets-w-billion-dollar-markets/
LMLLF’s flagship platform is PD-001 – a reformulated, patented version of cepharanthin, with laboratory data demonstrating potential therapies for a number of anticancer and antiviral indications. Cephrantine is a natural-based drug already approved in Japan, with a 70-year history of use. Cepharanthin has been shown in studies to both stop the spread and kill cancer cells, and reduce resistance to chemotherapy.
LMLLF’s PD-001 is a reformulation of the traditional pill form treatment used in Japan, but with 10 times greater bioavailability. The LMLLF sees its PD-001 as a platform to potentially address a wider range of cancer indications.
The LMLLF is currently advancing studies of PD-001 for the treatment of esophageal and prostate cancers. LMLLF has just received orphan drug designation from the FDA for PD-001 for esophageal cancer, a $1.5 billion market opportunity. Orphan drug designation allows for potentially expedited FDA approval, reduced development costs, and increased market protection. The LMLLF is also advancing PD-001 for prostate cancer, filing a provisional patent for cepharanthine combined with chemo for prostate cancer.
The LMLLF is also developing a treatment for glaucoma, based on a reformulation of DMT (N-Dimethyltryptamine) to reduce intraocular pressure. Tryptamines, including DMT, have been shown in clinical studies to reduce intraocular pressure. The LMLLF collaborates with the Terasaki Institute for Biomedical Innovation, a world-class leader in the development of new drug delivery technologies to optimize the formulation of DMT with a controlled release device. LMLLF Clinical Research has developed two candidate drug formulations, which have tested well for low toxicity and show promising potency and efficacy, and plans to initiate FDA clinical trials in the coming months. In his interview, CEO Dan Cophen also shares that LMLLF’s pipeline assets have significant upside potential as biotech valuations recover from current cyclical lows.
Watch the NEXT SUPER STOCK PharmaDrug ( LMLLF) (CSE: PHRX) video: https://www.wallstreetreporter.com/2022/03/31/next-super-stock-pharmadrug-otc-lmllf-cse-phrx-advancing-biopharm-assets-w-billion-dollar-markets/
Reenie McCarthy, CEO of Stealth BioTherapeutics ( MITO): “SBT-272 targets mitochondrial dysfunction”
Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of new SBT-272 preclinical data demonstrating functional improvement of upper motor neurons with TDP-43 pathology, which plays an important role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data was presented at the Keystone Neurodegeneration Symposium in Keystone, CO held June 5-9, 2022. A Phase 1 study to assess the safety and tolerability of SBT-272 in healthy volunteers is underway. Classes. MITO CEO Reenie McCarthy said, “ALS is a devastating progressive neuromuscular disease with a significant unmet medical need. We designed SBT-272 to target mitochondrial dysfunction in the brain, which is known to precede and contribute to several neurodegenerative diseases, including ALS. We are encouraged that Dr. Ozdinler’s team has elucidated these neural protective signals, and we look forward to working with the ALS community to advance the clinical development of SBT-272.
Stealth BioTherapeutics (MITO) News: https://www.wallstreetreporter.com/2022/06/08/stealth-biotherapeutics-nasdaq-mito-presents-new-sbt-272-data/
WALL STREET JOURNALIST
Wall Street Reporter (est. 1843) is the leading provider of financial information, focused on giving investors direct access to CEOs of promising publicly traded companies and market experts. www.WallStreetReporter.com. Nothing in this news summary should be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer and relevant SEC 17B disclosures here: https://tinyurl.com/2x4eznd5
About Wall Street Reporter’s Next Super Stock conference:
NEXT SUPER STOCK live from The Wall Street Reporter! The conference is dedicated to showcasing select companies that have put in place near-term catalysts that can drive transformational growth (and stock appreciation) in the months ahead. Click here to join the next live stream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/
CONTACT:
WALL STREET JOURNALIST
(212) 871-2057 ext 7
